FOXP3 and cervical cancer: The 3-year survival rate (54.3% vs. 91.4%), similarly, compared to the double negative group, the double positive expression of VISTA and Foxp3 shows the worst average survival (26.813 ± 3.584 vs. 52.929 ± 1.052), especially for patients in higher stage because VISTA and Foxp3 both can be found higher in stage II cervical cancer [54].